drugset / Trial / NCT02352285

Outcome and Treatment Quality Study of Tolvaptan to Treat Hyponatremia in Patients With Heart Failure

NCT02352285

Phase 4 Terminated 58 enrolled Korea Otsuka Pharmaceutical Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

The objective is to evaluate the efficacy and safety on the tolvaptan for increasing serum Na levels in patients with worsening heart failure and hyponatremia.

Timeline

Start
2012-12
Primary completion
2017-01
Completion
2017-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Tolvaptan Small molecule 60 mg Oral

Indications